abrdn Life Sciences Investors
HQL
65 hedge funds and large institutions have $52.3M invested in abrdn Life Sciences Investors in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 9 closing their positions.
28% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 18
0.46% less ownership
Funds ownership: 15.07% → 14.61% (-0.46%)
2% less funds holding
Funds holding: 66 → 65 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
14% less capital invested
Capital invested by funds: $60.6M → $52.3M (-$8.26M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$1.94M |
| 2 |
SFS
Shaker Financial Services
Arlington,
Virginia
|
+$613K |
| 3 |
SI
Stephens Inc
Little Rock,
Arkansas
|
+$492K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$341K |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$274K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Advisors Asset Management
Monument,
Colorado
|
-$957K |
| 2 |
Invesco
Atlanta,
Georgia
|
-$521K |
| 3 |
Morgan Stanley
New York
|
-$521K |
| 4 |
AUB
Atlantic Union Bankshares
Glen Allen,
Virginia
|
-$420K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$408K |
HQL Hedge Fund Activity: Q2 2022 in Review
65 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q2 2022, worth a combined $52.3M — down 14% from $60.6M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of HQL and 8 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 23 added.
The largest buyer was Wolverine Asset Management, adding an estimated $1.94M. The largest seller was Advisors Asset Management, cutting an estimated $957K.
- 65 institutional investors held abrdn Life Sciences Investors (HQL) as of Q2 2022, down from 66 in Q1 2022.
- Funds reported $52.3M of abrdn Life Sciences Investors stock for Q2 2022, down 14% quarter-over-quarter.
- 8 funds opened new abrdn Life Sciences Investors positions in Q2 2022 and 9 closed out, a net change of -1 holder.
- The largest abrdn Life Sciences Investors buyer in Q2 2022 was Wolverine Asset Management, an estimated $1.94M added.
- The largest abrdn Life Sciences Investors seller in Q2 2022 was Advisors Asset Management, an estimated $957K sold.
Based on aggregated 13F filings for Q2 2022.